Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 139

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 139
---
 or other third parties may assert infringement claims against us,
alleging that our product candidates are covered by their patents. We cannot be certain that we do not infringe existing patents or that
we will not infringe patents that may be granted in the future. There is a substantial amount of litigation, both within and outside
the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including
patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter partes review, and
post-grant review before the USPTO, as well as oppositions and similar processes in other jurisdictions. Numerous U.S. and non-U.S. issued
patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are
developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain
greater visibility, the risk increases that our product candidates or other business activities may be subject to claims of infringement
of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing
their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials,
formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.

71

Additionally, because patent applications can take many years
to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may
infringe that we are not aware of. In addition, third parties may obtain patents in the future and claim that use of our technologies
infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover any of our product
candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained
a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent
jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders
of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a
license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.
Claims that we